SanBio is focused on therapies for neurological disorders such as stroke, spinal cord injury, Parkinson's disease and multiple sclerosis.

SanBio is a scientific leader in cell therapies for regenerative medicine. SanBio's products have achieved extraordinary results in animal models of a number of important disorders and having received FDA Investigational New Drug approval, have initiated a Phase I/IIa clinical trial for stroke disability. Read more...

SanBio is now recruiting patients for a clinical trial testing a new cell therapy
for stable stroke.

Use this UCSF questionnaire to
determine if you may be eligible.
ABOUT THE STUDY

A clinical trial is testing SB623, an adult stem cell therapy. In animal studies, measurable improvements in use of limbs have been shown. In this clinical study, safety as well as therapeutic potential will be evaluated. Read more....

News